Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA127
  • Published: 

NICE recommends natalizumab for the treatment of multiple sclerosis

The National Institute for Health and Clinical Excellence (NICE) has today issued guidance recommending natalizumab for the treatment of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). This guidance is produced as part of its rapid single technology appraisal (STA) work programme.

This page was last updated: 30 March 2010